CO5690657A2 - METHOD FOR PRODUCING CARBOXILATED GAMMA PROTEINS - Google Patents

METHOD FOR PRODUCING CARBOXILATED GAMMA PROTEINS

Info

Publication number
CO5690657A2
CO5690657A2 CO06035799A CO06035799A CO5690657A2 CO 5690657 A2 CO5690657 A2 CO 5690657A2 CO 06035799 A CO06035799 A CO 06035799A CO 06035799 A CO06035799 A CO 06035799A CO 5690657 A2 CO5690657 A2 CO 5690657A2
Authority
CO
Colombia
Prior art keywords
promoter
protein
expression
gamma
requires
Prior art date
Application number
CO06035799A
Other languages
Spanish (es)
Inventor
Christel Fenge
Ann Lovgren
Anders Thelin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29559260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5690657(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5690657A2 publication Critical patent/CO5690657A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

1.- Reivindicación(es): Una célula anfitrión que comprende un vector de expresión que comprende una.molécula de ácido nucleico que codifica una proteína que requiere una gamma carboxilaci6n y las secuencias asociadas al control de la expresión que comprende un primer promotor y una molécula de ácido nucleico que codifica una y-glutamil carboxilasa y las secuencias asociadas al control de la expresión que comprende un segundo promotor, donde el primer promotor es suficientemente más fuerte que el segundo promotor de manera que la proteína que requiere una gamma carboxilaci6n y la y-glutamil carboxilasa se expresan en una proporción de por lo menos 10:1.15.- Un vector que comprende una molécula de ácido nucleico que codifica una proteína que requiere una gamma carboxilación y las secuencias asociadas al control de la expresión que comprenden un primer promotor y una molécula de ácido nucleico que codifica una ?-glutamil carboxilasa y las secuencias asociadas al control de la expresión que comprenden un segundo promotor, donde el primer promotor es suficientemente más fuerte que el segundo promotor de manera que la proteína que requiere una gamma carboxilación y la ? -glutamil carboxilasa se expresan en una proporción de por lo menos 10:1.21.- Un método para producir una proteína gamma-carboxilada que comprende: (i) cultivar una célula adaptada para expresar una proteína que requiere una gamma carboxilación y ?-glutamil carboxilasa en una proporción de por lo menos 10:1, bajo condiciones apropiadas para la expresión de ambas proteínas y (ii) aislar la proteína gamma-carboxilada.1. Claim (s): A host cell comprising an expression vector comprising a nucleic acid molecule encoding a protein that requires a gamma carboxylation and the sequences associated with the control of expression comprising a first promoter and a nucleic acid molecule encoding a y-glutamyl carboxylase and the sequences associated with expression control comprising a second promoter, where the first promoter is sufficiently stronger than the second promoter such that the protein that requires a gamma carboxylation and the y-glutamyl carboxylase are expressed in a proportion of at least 10: 1.15.- A vector comprising a nucleic acid molecule encoding a protein that requires a gamma carboxylation and the sequences associated with the control of expression comprising a first promoter and a nucleic acid molecule encoding a? -glutamyl carboxylase and the sequences associated with the contr ol of the expression comprising a second promoter, where the first promoter is sufficiently stronger than the second promoter so that the protein that requires a gamma carboxylation and the? -glutamyl carboxylase is expressed in a proportion of at least 10: 1.21.- A method of producing a gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein that requires a gamma carboxylation and? -glutamyl carboxylase in a ratio of at least 10: 1, under appropriate conditions for the expression of both proteins and (ii) isolate the gamma-carboxylated protein.

CO06035799A 2003-10-14 2006-04-12 METHOD FOR PRODUCING CARBOXILATED GAMMA PROTEINS CO5690657A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0324044.7A GB0324044D0 (en) 2003-10-14 2003-10-14 Protein

Publications (1)

Publication Number Publication Date
CO5690657A2 true CO5690657A2 (en) 2006-10-31

Family

ID=29559260

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06035799A CO5690657A2 (en) 2003-10-14 2006-04-12 METHOD FOR PRODUCING CARBOXILATED GAMMA PROTEINS

Country Status (29)

Country Link
US (2) US7842477B2 (en)
EP (2) EP2292748B1 (en)
JP (1) JP4658946B2 (en)
KR (1) KR101201020B1 (en)
CN (2) CN102443548B (en)
AR (1) AR046180A1 (en)
AT (1) ATE491789T1 (en)
AU (2) AU2004281350B2 (en)
BR (1) BRPI0415277A (en)
CA (1) CA2541764C (en)
CO (1) CO5690657A2 (en)
DE (1) DE602004030603D1 (en)
DK (1) DK1678297T3 (en)
ES (2) ES2532470T3 (en)
GB (1) GB0324044D0 (en)
HK (1) HK1155475A1 (en)
IL (2) IL174633A (en)
IS (1) IS8447A (en)
MX (1) MXPA06004060A (en)
MY (1) MY141859A (en)
NO (1) NO339740B1 (en)
NZ (2) NZ546584A (en)
PL (1) PL1678297T3 (en)
PT (1) PT1678297E (en)
RU (2) RU2372401C2 (en)
TW (1) TWI355419B (en)
UY (1) UY28558A1 (en)
WO (1) WO2005038019A1 (en)
ZA (1) ZA200603038B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2453895T3 (en) * 2003-09-23 2014-04-08 University Of North Carolina At Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
CA2601574C (en) * 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US7989193B2 (en) * 2005-04-13 2011-08-02 Medimmune Limited Compositions and methods for producing gamma-carboxylated proteins
CA2624072A1 (en) * 2005-09-30 2007-04-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing recombinant human thrombin by cultured cell
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
ES2503365T5 (en) * 2005-12-21 2017-10-31 Cnj Holdings, Inc Method for producing biologically active vitamin K dependent proteins by recombinant methods
EP2407561A3 (en) * 2006-03-06 2012-05-30 Humagene, Inc. A method for the preparation of recombinant human fibrinogen
CA2683423C (en) * 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
CA2812888A1 (en) * 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina Methods and compositions for producing active vitamin k-dependent proteins
JP2014525475A (en) 2011-09-06 2014-09-29 メディミューン，エルエルシー How to process clotting factors
RU2500816C1 (en) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") RECOMBINANT PLASMID DNA pAK380 CODING POLYPEPTIDE OF RECOMBINANT FACTOR IX OF HUMAN BLOOD COAGULABILITY, LINE OF CELLS Cricetulus griseus CHO, 1E6-PRODUCER OF RECOMBINANT FACTOR IX OF HUMAN BLOOD COAGULABILITY, AND METHOD FOR OBTAINING POLYPEPTIDE HAVING ACTIVITY OF RECOMBINANT FACTOR IX
JP5830486B2 (en) 2013-03-29 2015-12-09 シスメックス株式会社 Recombinant baculovirus and use thereof
EP3604332A1 (en) * 2013-12-20 2020-02-05 Novartis AG Novel eukaryotic cells and methods for recombinantly expressing a product of interest
CN109207462B (en) * 2018-08-01 2021-05-11 深圳市新产业生物医学工程股份有限公司 Abnormal prothrombin, preparation method thereof, detection agent containing abnormal prothrombin, kit and application

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (en) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg METHOD FOR THE PRODUCTION OF BLOOD coagulation FACTORS AND THE PREPARATION OF FACTORS II AND VII THEREFORE PRODUCED
US4599308A (en) * 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (en) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター Enhancement of gamma carboxylation of recombinant vitamin K-dependent proteins
US6224864B1 (en) 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
CA1330302C (en) 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
AU8427091A (en) 1990-07-23 1992-02-18 Zymogenetics Inc. Gamma-carboxylase and methods of use
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (en) 1994-08-26 1996-02-29 Behringwerke Ag Medicament, which is suitable as an antidote for blood anticoagulants and its use
CZ81997A3 (en) 1996-03-20 1997-10-15 Immuno Ag Pharmaceutical preparation for treating disorders connected with blood clotting, process of its preparation and use
AU735463B2 (en) * 1997-02-14 2001-07-12 American Red Cross Expression of active human factor IX in mammary tissue of transgenic animals
AU2015799A (en) 1997-12-24 1999-07-19 Immunex Corporation V201 dna and polypeptides
EP1196610A2 (en) 1999-07-09 2002-04-17 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
WO2001007068A1 (en) 1999-07-23 2001-02-01 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
AU2001268373A1 (en) * 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
BR0114374A (en) * 2000-10-02 2003-12-30 Novo Nordisk As Preparation comprising a plurality of factor vii polypeptides, methods for determining the pattern of factor vii glycoform and factor vii-related polypeptides, and for producing said preparation, pharmaceutical formulation, methods for treating a factor responsive syndrome. vii, for the prevention of unwanted bleeding, for the prevention of unwanted blood clotting, and for the prevention of tissue factor mediated reactions, and the use of the preparation.
EP1405912B8 (en) 2001-07-06 2012-10-24 The Chemo-Sero-Therapeutic Research Institute Genetically modified ecarin and process for producing the same
ATE423199T1 (en) 2001-07-06 2009-03-15 Chemo Sero Therapeut Res Inst METHOD FOR PRODUCING HUMAN THROMBIN USING GENETIC MODIFICATION TECHNOLOGY
EP1407780B1 (en) 2001-07-10 2013-05-01 The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
ES2453895T3 (en) 2003-09-23 2014-04-08 University Of North Carolina At Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP1673450B1 (en) 2003-10-14 2010-04-28 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US7829306B2 (en) 2003-10-24 2010-11-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Protein highly producing recombinant animal cell, method for preparing the same, and method for mass-producing protein using the same
JP2008523837A (en) 2004-12-21 2008-07-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Expression of gamma-carboxylated polypeptides in host systems defective in gamma-carboxylation
US7989193B2 (en) 2005-04-13 2011-08-02 Medimmune Limited Compositions and methods for producing gamma-carboxylated proteins
CA2632794C (en) 2005-12-02 2015-04-07 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
ES2503365T5 (en) 2005-12-21 2017-10-31 Cnj Holdings, Inc Method for producing biologically active vitamin K dependent proteins by recombinant methods
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
BRPI0415277A (en) 2006-12-19
KR101201020B1 (en) 2012-11-14
IS8447A (en) 2006-05-10
PT1678297E (en) 2011-03-15
AR046180A1 (en) 2005-11-30
UY28558A1 (en) 2005-05-31
AU2008205445A1 (en) 2008-09-04
CN1867669B (en) 2011-10-19
NO20061470L (en) 2006-05-12
MY141859A (en) 2010-07-16
TWI355419B (en) 2012-01-01
DK1678297T3 (en) 2011-03-14
NO339740B1 (en) 2017-01-30
HK1155475A1 (en) 2012-05-18
US20050164367A1 (en) 2005-07-28
WO2005038019A1 (en) 2005-04-28
AU2004281350A1 (en) 2005-04-28
JP4658946B2 (en) 2011-03-23
ATE491789T1 (en) 2011-01-15
NZ578306A (en) 2011-02-25
US20110092429A1 (en) 2011-04-21
RU2372401C2 (en) 2009-11-10
JP2007508820A (en) 2007-04-12
IL226313A0 (en) 2013-06-27
ZA200603038B (en) 2007-09-26
EP2292748B1 (en) 2014-12-17
ES2357603T3 (en) 2011-04-28
PL1678297T3 (en) 2011-11-30
EP1678297B1 (en) 2010-12-15
DE602004030603D1 (en) 2011-01-27
CA2541764A1 (en) 2005-04-28
RU2006110147A (en) 2007-11-20
ES2532470T3 (en) 2015-03-27
AU2004281350B2 (en) 2008-05-15
NZ546584A (en) 2009-08-28
EP1678297A1 (en) 2006-07-12
GB0324044D0 (en) 2003-11-19
TW200523365A (en) 2005-07-16
US7842477B2 (en) 2010-11-30
EP2292748A1 (en) 2011-03-09
CN1867669A (en) 2006-11-22
CN102443548A (en) 2012-05-09
MXPA06004060A (en) 2006-06-28
US8697440B2 (en) 2014-04-15
CA2541764C (en) 2015-03-31
RU2009123931A (en) 2010-12-27
KR20060123152A (en) 2006-12-01
CN102443548B (en) 2014-03-12
IL174633A0 (en) 2006-08-20
IL174633A (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CO5690657A2 (en) METHOD FOR PRODUCING CARBOXILATED GAMMA PROTEINS
Bajaj et al. Simultaneous purification of bovine prothrombin and factor X: Activation of prothrombin by trypsin-activated factor X
Kobayashi et al. Biochemical studies on sulfate-reducing bacteria XI. Purification and some properties of sulfite reductase, desulfoviridin
DE602005011486D1 (en) ACID FUNGUS PROTEASE IN THE FERMENTATION OF NON-SOLUBLE STARRY SUBSTRATES
WO2003106684A3 (en) A method for simultaneous production of multiple proteins; vectors and cells for use therein
MX2007003906A (en) Methods and compositions for improving recombinant protein production.
FR2822164B1 (en) POLYPEPTIDES DERIVED FROM POLYMERASE RNAS, AND USES THEREOF
WO2002031134A3 (en) Novel serine protease genes related to dppiv
BR112014023869A2 (en) loaded nutrient proteins and methods
CU23791A3 (en) METHOD FOR THE PRODUCTION OF IMPROVED PROTEINS AND ANTIBODIES
DE60335195D1 (en) MUTANT E. COLI-APPA-PHYTASEENZYME AND NATURAL VARIANTS THEREOF, SUCH NUCLEIC ACIDS CODING PHYTASEASE SYMBOLS, VECTORS AND HOST CELLS CONTAINING THEREOF, AND METHOD FOR THE PREPARATION AND USE THEREOF
DE602004021836D1 (en) MEG1 ENDOSPERME SPECIFIC PROMOTERS AND GENES
ATE465241T1 (en) METHOD FOR THE FERMENTATIVE PRODUCTION OF PROTEINS
DE60142226D1 (en) MUSHROOM TRANSCRIPTION ACTIVATOR FOR USE IN PROCESSES FOR THE PREPARATION OF POLYPEPTIDES
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
DE10345772A1 (en) Process for the preparation of 3-methylamino-1- (thien-2-yl) -propan-1-ol
WO2003106674A3 (en) Use of repression blocking sequences in methods for enhancing gene expression
EA200801873A1 (en) NEW LIPASE AND THEIR APPLICATION
ATE383420T1 (en) USE OF THE CYP52A2A PROMOTER TO INCREASE GENE EXPRESSION IN YEAST
DE50115438D1 (en) Nucleotide sequences encoding the dapC gene and methods of producing L-lysine
BRPI0406265B8 (en) method for analysis by capillary electrophoresis, method for research and typing of monoclonal proteins, method of preparation of negatively supercharged modified antibodies and kit for detection and typing of monoclonal proteins
Trader et al. Hemoglobin: molecular changes during anuran metamorphosis
AR120690A1 (en) MODIFIED DAAO AND USE OF THE SAME
Zera et al. Purification and characterization of hemolymph juvenile hormone esterase from the cricket, Gryllus assimilis
HUP0002234A2 (en) Vascular adhesion protein-1 having oxidase activity

Legal Events

Date Code Title Description
FC Application refused